Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
SGEN's Cash to Debt is ranked higher than
98% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. SGEN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
SGEN' s Cash to Debt Range Over the Past 10 Years
Min: No Debt  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.78
SGEN's Equity to Asset is ranked higher than
62% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SGEN: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
SGEN' s Equity to Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.59 Max: 0.96
Current: 0.78
0.36
0.96
F-Score: 3
Z-Score: 15.49
M-Score: 1.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -32.87
SGEN's Operating margin (%) is ranked higher than
59% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. SGEN: -32.87 )
Ranked among companies with meaningful Operating margin (%) only.
SGEN' s Operating margin (%) Range Over the Past 10 Years
Min: -401.85  Med: -157.83 Max: -23.35
Current: -32.87
-401.85
-23.35
Net-margin (%) -32.61
SGEN's Net-margin (%) is ranked higher than
59% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. SGEN: -32.61 )
Ranked among companies with meaningful Net-margin (%) only.
SGEN' s Net-margin (%) Range Over the Past 10 Years
Min: -359.97  Med: -158.80 Max: -23.22
Current: -32.61
-359.97
-23.22
ROE (%) -24.29
SGEN's ROE (%) is ranked higher than
57% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. SGEN: -24.29 )
Ranked among companies with meaningful ROE (%) only.
SGEN' s ROE (%) Range Over the Past 10 Years
Min: -128.57  Med: -40.02 Max: -24.17
Current: -24.29
-128.57
-24.17
ROA (%) -16.87
SGEN's ROA (%) is ranked higher than
61% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. SGEN: -16.87 )
Ranked among companies with meaningful ROA (%) only.
SGEN' s ROA (%) Range Over the Past 10 Years
Min: -50.86  Med: -28.26 Max: -12
Current: -16.87
-50.86
-12
ROC (Joel Greenblatt) (%) -254.01
SGEN's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. SGEN: -254.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SGEN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -903.49  Med: -523.09 Max: -178.02
Current: -254.01
-903.49
-178.02
Revenue Growth (3Y)(%) 40.50
SGEN's Revenue Growth (3Y)(%) is ranked higher than
86% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. SGEN: 40.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SGEN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 7.7  Med: 40.50 Max: 148.1
Current: 40.5
7.7
148.1
EBITDA Growth (3Y)(%) -24.90
SGEN's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. SGEN: -24.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SGEN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.1  Med: -1.70 Max: 18.5
Current: -24.9
-30.1
18.5
EPS Growth (3Y)(%) -22.90
SGEN's EPS Growth (3Y)(%) is ranked lower than
71% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. SGEN: -22.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SGEN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -34.2  Med: -4.75 Max: 27.7
Current: -22.9
-34.2
27.7
» SGEN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

SGEN Guru Trades in Q2 2015

Vanguard Health Care Fund 170,125 sh (New)
PRIMECAP Management 11,899,100 sh (+0.53%)
Columbia Wanger 2,355,005 sh (-30.90%)
Manning & Napier Advisors, Inc 252,470 sh (-48.76%)
» More
Q3 2015

SGEN Guru Trades in Q3 2015

Paul Tudor Jones 22,173 sh (New)
John Burbank 159,966 sh (New)
Jim Simons 15,880 sh (New)
Ray Dalio 36,000 sh (New)
PRIMECAP Management 12,865,950 sh (+8.13%)
Vanguard Health Care Fund 170,125 sh (unchged)
Manning & Napier Advisors, Inc 252,470 sh (unchged)
Columbia Wanger 1,842,396 sh (-21.77%)
» More
Q4 2015

SGEN Guru Trades in Q4 2015

Manning & Napier Advisors, Inc 357,750 sh (+41.70%)
PRIMECAP Management 12,882,175 sh (+0.13%)
Vanguard Health Care Fund Sold Out
Jim Simons Sold Out
Ray Dalio Sold Out
John Burbank Sold Out
Paul Tudor Jones Sold Out
Columbia Wanger 1,621,001 sh (-12.02%)
» More
Q1 2016

SGEN Guru Trades in Q1 2016

Columbia Wanger 1,763,796 sh (+8.81%)
PRIMECAP Management 13,589,187 sh (+5.49%)
Manning & Napier Advisors, Inc 289,140 sh (-19.18%)
» More
» Details

Insider Trades

Latest Guru Trades with SGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:OPK, NAS:DYAX, OTCPK:SBMFF, NAS:ALNY, NAS:UTHR, NAS:ANAC, NAS:JUNO, NAS:TECH, NAS:ALKS, OTCPK:BTGGF, NAS:ACAD, NAS:ICPT, OTCPK:LBTSF, NYSE:XON, NAS:CBPO, NAS:IONS, OTCPK:SOLTF, NAS:KITE, NAS:LGND, NAS:JAZZ » details
Traded in other countries:SGT.Germany,
Seattle Genetics Inc is a biotechnology company. It develops and commercializes monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease.

Seattle Genetics Inc was incorporated on July 15, 1997. It is a biotechnology company focused on the development and commercialization of targeted therapies for the treatment of cancer. Its marketed product ADCETRIS, or brentuximab vedotin, is approved by the United States Food and Drug Administration, or FDA, for three indications, encompassing several settings for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma, or sALCL. ADCETRIS is commercially available in more than 60 countries around the world, including in the United States, Canada, members of the European Union and Japan. It is collaborating with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS on a global basis. Under this collaboration, Seattle Genetics retains commercial rights for ADCETRIS in the United States and its territories and in Canada, and Takeda has commercial rights in the rest of the world. In addition to ADCETRIS and SGN-CD33A, its clinical-stage pipeline includes five other antibody-drug conjugate, or ADC, programs consisting of SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and an immuno-oncology agent called SEA-CD40, which is based on our sugar-engineered antibody, or SEA, technology. It sells ADCETRIS through a limited number of pharmaceutical distributors.. Many third parties compete with the Company in developing various approaches to cancer and autoimmune disease therapy. It includes pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. The Company operates under the regulations of FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.

Top Ranked Articles about Seattle Genetics Inc

Vanguard Health Care Fund Buys 2 New Stakes in Second Quarter
As its name suggests, Vanguard Health Care Fund (Trades, Portfolio) invests almost exclusively in health care companies. It’s been a successful investment niche. Vanguard enjoyed returns exceeding 28% in 2014, 43% in 2013 and 15% in 2012. Read more...

Ratios

vs
industry
vs
history
P/B 8.25
SGEN's P/B is ranked lower than
78% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. SGEN: 8.25 )
Ranked among companies with meaningful P/B only.
SGEN' s P/B Range Over the Past 10 Years
Min: 1.88  Med: 8.78 Max: 35.99
Current: 8.25
1.88
35.99
P/S 14.43
SGEN's P/S is ranked lower than
57% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. SGEN: 14.43 )
Ranked among companies with meaningful P/S only.
SGEN' s P/S Range Over the Past 10 Years
Min: 9.87  Med: 19.29 Max: 45.24
Current: 14.43
9.87
45.24
Current Ratio 6.00
SGEN's Current Ratio is ranked higher than
59% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SGEN: 6.00 )
Ranked among companies with meaningful Current Ratio only.
SGEN' s Current Ratio Range Over the Past 10 Years
Min: 2.65  Med: 5.23 Max: 30.03
Current: 6
2.65
30.03
Quick Ratio 5.51
SGEN's Quick Ratio is ranked higher than
58% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. SGEN: 5.51 )
Ranked among companies with meaningful Quick Ratio only.
SGEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.29  Med: 5.05 Max: 30.03
Current: 5.51
2.29
30.03
Days Inventory 476.56
SGEN's Days Inventory is ranked lower than
94% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. SGEN: 476.56 )
Ranked among companies with meaningful Days Inventory only.
SGEN' s Days Inventory Range Over the Past 10 Years
Min: 442.93  Med: 557.12 Max: 639.76
Current: 476.56
442.93
639.76
Days Sales Outstanding 52.28
SGEN's Days Sales Outstanding is ranked higher than
58% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. SGEN: 52.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.55  Med: 61.69 Max: 562.77
Current: 52.28
25.55
562.77
Days Payable 196.48
SGEN's Days Payable is ranked higher than
84% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 59.87 vs. SGEN: 196.48 )
Ranked among companies with meaningful Days Payable only.
SGEN' s Days Payable Range Over the Past 10 Years
Min: 216.62  Med: 290.02 Max: 1833.79
Current: 196.48
216.62
1833.79

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.64
SGEN's Price/Net Cash is ranked lower than
74% of the 504 Companies
in the Global Biotechnology industry.

( Industry Median: 5.38 vs. SGEN: 13.64 )
Ranked among companies with meaningful Price/Net Cash only.
SGEN' s Price/Net Cash Range Over the Past 10 Years
Min: 2.12  Med: 10.94 Max: 284.71
Current: 13.64
2.12
284.71
Price/Net Current Asset Value 10.46
SGEN's Price/Net Current Asset Value is ranked lower than
70% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. SGEN: 10.46 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SGEN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.09  Med: 9.59 Max: 447
Current: 10.46
2.09
447
Price/Tangible Book 8.27
SGEN's Price/Tangible Book is ranked lower than
71% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. SGEN: 8.27 )
Ranked among companies with meaningful Price/Tangible Book only.
SGEN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.78  Med: 5.80 Max: 33.75
Current: 8.27
1.78
33.75
Price/Median PS Value 0.75
SGEN's Price/Median PS Value is ranked higher than
67% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. SGEN: 0.75 )
Ranked among companies with meaningful Price/Median PS Value only.
SGEN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.52  Med: 1.12 Max: 30
Current: 0.75
0.52
30
Earnings Yield (Greenblatt) (%) -2.38
SGEN's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. SGEN: -2.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SGEN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4.02  Med: 0.00 Max: 0
Current: -2.38
-4.02
0

More Statistics

Revenue (TTM) (Mil) $365.8
EPS (TTM) $ -0.92
Beta2.00
Short Percentage of Float24.50%
52-Week Range $26.02 - 52.33
Shares Outstanding (Mil)140.17

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 421 478 658
EPS ($) -1.04 -0.82 -0.06
EPS w/o NRI ($) -1.04 -0.82 -0.06
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for SGEN

Headlines

Articles On GuruFocus.com
Insiders Roundup: Theravance Biopharma, Western Gas, Upland Software Mar 18 2016 
Top Insider Trades of the Past Week Feb 19 2016 
Insiders Are Buying Barnes & Noble Sep 18 2015 
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
Insiders keep on buying Macerich Co and Seattle Genetics May 22 2015 
Insiders new buys : ZU, SGEN, MAC, SHLD, TBRA May 12 2015 
Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 

More From Other Websites
5 Best-Positioned Biotech Stocks on Brexit Volatility Jun 28 2016
Seattle-area stocks: Brexit news punishes Tableau, Juno, Paccar in Friday trading Jun 24 2016
Seattle Genetics, Inc. – Value Analysis (NASDAQ:SGEN) : June 21, 2016 Jun 21 2016
Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : June 20,... Jun 20 2016
Agios Upgraded As Anemia Drug Data Soothes Safety Concerns Jun 13 2016
Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML)... Jun 11 2016
IBB Holdings: How Are Their Moving Averages Trending? Jun 09 2016
Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in... Jun 06 2016
Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in... Jun 06 2016
Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic... Jun 06 2016
XBI Mid-Caps: Seattle Genetics Rose Due to Higher Trading Volumes May 27 2016
Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug May 26 2016
SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers, Submission... May 25 2016
Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients... May 25 2016
A Scarcity of Biotech Assets for Buyouts? May 20 2016
ETF’s with exposure to Seattle Genetics, Inc. : May 19, 2016 May 19 2016
Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : May 18,... May 18 2016
SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers May 13 2016
SEATTLE GENETICS INC /WA Financials May 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)